Zacks Investment Research·2d ago
Ocugen's Q3 Earnings Match Estimates, Revenues Beat, Stock RisesOCGN's Q3 revenues beat estimates. Shares surge 17.4%.
Ocugen's fundamental picture remains pre-commercial and loss-making, with revenue stuck near $1.5M per quarter against operating expenses of roughly $17.9M in 2026Q2 — a ratio of roughly 12x — while R&D held at $10.7M without any visible revenue inflection.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 4, 2026 | -$0.06+0.0% vs -$0.06 | $2M+48.1% vs $1M |
Q3 2026 Aug 6, 2026 | -$0.07-31.3% vs -$0.05 | $1M+67.4% vs $888,833 |
Q2 2026 May 5, 2026 | -$0.06-20.0% vs -$0.05 | $2M+266.9% vs $417,833 |
Q2 2026 Mar 4, 2026 | -$0.06+0.0% vs -$0.06 | $193,000-118.0% vs $1M |
OCGN's Q3 revenues beat estimates. Shares surge 17.4%.
Ocugen, Inc. ( OCGN ) Q3 2026 Earnings Call November 4, 2026 8:30 AM EST Company Participants Chris Clark - VP of Corporate Communications Shankar Musunuri - Co-Founder, CEO & Chairman Rita Johnson-Greene - CFO & Principal Accounting Officer Mohamed Genead - Chief Medical Officer Abhi Gupta - Executive Vice President of Commercial and Business Development Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research Division Robert LeBoyer - NOBLE Capital Markets, Inc., Research Division Michael Okunewitch - Maxim Group LLC, Research Division Elemer Piros - Lucid Capital Markets, LLC, Research Division Leland Gershell - Oppenheimer & Co. Inc., Research Division Whitney Ijem - Canaccord Genuity Corp., Research Division Presentation Operator Good morning, and welcome to Ocugen's Third Quarter 2026 Financial Results and Business Update.
Ocugen NASDAQ: OCGN said its third-quarter progress centered on advancing three retinal gene therapy programs in late-stage development, expanding regional partnerships and establishing a European presence to support future commercialization efforts.
Ocugen (OCGN) came out with a quarterly loss of $0.06 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.07 per share a year ago.
Benchmark OCGN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Ocugen, Inc. (OCGN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.93 | $313.68M | -4.80 | 8.83% | -1367.61% | -776.89% | — | |
| $21.62 | $1.82B | -8.39 | — | — | -157.78% | — | |
| $2.57 | $394.4M | -4.15 | 25.39% | -157.32% | -196.63% | — | |
| $26.41 | $2.72B | -25.82 | 120.01% | -73.04% | -9.69% | — | |
| $11.35 | $1.27B | -3.73 | 16.92% | -805.75% | -64.73% | — | |
| $50.07 | $4.83B | -10.62 | -89.97% | -1812.07% | -25.59% | — |
Ocugen, Inc. (OCGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Ocugen, Inc. (OCGN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jul 13, 2026·SEC
Jun 11, 2026·SEC
Get notified when OCGN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Ocugen, Inc. (OCGN) stock FAQ — growth, dividends, profitability & financials explained
Ocugen, Inc. (OCGN) reported $4.8M in revenue over the trailing twelve months. Revenue was $4.4M in fiscal year 2025. That is 16873% more than the $0.0M of fiscal year 2012.
Ocugen, Inc. (OCGN) revenue fell by 11.0% over the trailing twelve months, compared with the twelve months before.
No. Ocugen, Inc. (OCGN) reported a net loss of $65.4M over the trailing twelve months.
Ocugen, Inc. (OCGN) had a return on equity (ROE) of -776.9% in fiscal year 2025. A negative ROE means the company lost money over the period.
Ocugen, Inc. (OCGN) had negative free cash flow of $63.9M over the trailing twelve months.
